Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
Description: Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel, oral antivirals to address unmet medical needs in the United States. Its lead compounds include brincidofovir (CMX001), which is in Phase III clinical development; CMX157, a nucleotide analog that has completed Phase I study for the treatment of HIV infections. The company?s proprietary lipid technology and chemical library is under discovery and preclinical stage of development. It has collaboration and license agreement with Merck Sharp & Dohme Corp. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||34.71%||Sales Growth - Q/Q||7.09%||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-25.97%||ROE||-27.65%||ROI|
|Current Ratio||10.78||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.06|
|Gross Margin||Operating Margin||-1578.72%||Net Profit Margin||-1582.88%||Dividend Payout Ratio|
|Cash From Financing Activities||700 K||Cash From Investing Activities||-54.72 M||Cash From Operating Activities||-18.84 M||Gross Profit|
|Net Profit||-22.27 M||Operating Profit||-22.33 M||Total Assets||274.12 M||Total Current Assets||177.26 M|
|Total Current Liabilities||16.44 M||Total Debt||2.89 M||Total Liabilities||16.6 M||Total Revenue||1.24 M|
|High 52 week||4.9||Low 52 week||1.79||Last close||3.5||Last change||-4.37%|
|RSI||73.17||Average true range||0.24||Beta||1.18||Volume||236.01 K|
|Simple moving average 20 days||19.72%||Simple moving average 50 days||40.3%||Simple moving average 200 days||14.21%|
|Performance Week||12.18%||Performance Month||34.1%||Performance Quart||75.88%||Performance Half||10.41%|
|Performance Year||-27.98%||Performance Year-to-date||36.19%||Volatility daily||4.29%||Volatility weekly||9.6%|
|Volatility monthly||19.66%||Volatility yearly||68.12%||Relative Volume||181.52%||Average Volume||591.99 K|
|New High||New Low|
2019-08-08 09:35:01 | Chimerix CMRX Reports Q2 Loss, Lags Revenue Estimates
2019-08-08 08:00:00 | Chimerix Announces Second Quarter 2019 Financial Results and Operational Update
2019-08-07 10:30:02 | Chimerix CMRX Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
2019-08-05 07:55:16 | Durham pharma spends $30 million for rights to potential Leukemia treatment
2019-07-12 15:07:33 | Do Institutions Own Chimerix, Inc. NASDAQ:CMRX Shares?
2019-06-28 18:41:45 | Did Hedge Funds Drop The Ball On Chimerix Inc CMRX ?
2019-05-16 09:11:01 | Will Chimerix to Surge Higher?
2019-05-09 14:08:22 | Edited Transcript of CMRX earnings conference call or presentation 9-May-19 12:30pm GMT
2019-05-09 09:25:01 | Chimerix CMRX Reports Q1 Loss, Tops Revenue Estimates
2019-05-09 08:25:59 | Chimerix: 1Q Earnings Snapshot
2019-05-09 08:00:00 | Chimerix Announces First Quarter 2019 Financial Results and Strategy Update
2019-05-09 06:30:00 | Chimerix, Inc. to Host Earnings Call
2019-05-02 16:01:00 | Chimerix to Announce First Quarter 2019 Financial Results on May 9, 2019
2019-04-29 10:31:02 | Will Chimerix CMRX Report Negative Q1 Earnings? What You Should Know
2019-04-12 13:43:38 | One Thing To Remember About The Chimerix, Inc. NASDAQ:CMRX Share Price
2019-04-09 11:21:50 | Chimerix taps former Endocyte executive as new CEO
2019-04-08 17:00:00 | Chimerix Announces Management Updates
2019-04-05 14:14:57 | Again, Durham pharma loses a drug development partner
2019-03-07 12:24:00 | Should You Be Worried About Insider Transactions At Chimerix, Inc. NASDAQ:CMRX?
2019-03-05 16:09:29 | Edited Transcript of CMRX earnings conference call or presentation 5-Mar-19 1:30pm GMT
2019-03-05 07:00:00 | Chimerix Announces Fourth Quarter and Full Year 2018 Financial Results
2019-03-04 08:00:00 | Chimerix to Present at Cowen and Company 39th Annual Health Care Conference
2019-02-22 08:00:00 | Chimerix Presents Results from Post-hoc Analysis of Phase 3 Study
2019-02-14 08:15:22 | Chimerix filing reveals ex-CEO's severance package after sudden resignation
2019-02-11 07:55:00 | New Research Coverage Highlights United Parcel Service, Healthcare Trust of America, CommVault, SPX FLOW, Chimerix, and International Speedway — Consolidated Revenues, Company Growth, and Expectations for 2019
2019-02-06 14:20:49 | Sudden Departure: Chimerix CEO, board member resigns
2019-02-06 08:00:00 | Chimerix Announces Management Transition
2019-01-30 11:51:55 | What Type Of Shareholder Owns Chimerix, Inc.’s NASDAQ:CMRX?
2019-01-24 10:17:03 | Will Overall Growth Aid Thermo Fisher's TMO Q4 Earnings?
2019-01-24 10:03:03 | Can Solid Consumables Drive Illumina's ILMN Q4 Earnings?
2019-01-18 06:36:11 | What Lies Ahead for Abbott ABT Stock This Earnings Season?
2019-01-17 09:38:02 | 4 Medical Product Stocks Likely to Top Q4 Earnings Estimates
2019-01-04 07:30:00 | Chimerix to Present at the 37th Annual J.P. Morgan Healthcare Conference
2018-12-27 09:23:36 | Stocks down in December for pharma firms in the Triangle
2018-12-22 04:43:29 | Should You Avoid Chimerix Inc CMRX?
2018-12-18 08:35:01 | 5 Beaten-Down Medical Product Stocks to Rebound in 2019
2018-12-12 11:26:38 | Is Chimerix, Inc. NASDAQ:CMRX Overpaying Its CEO?
2018-11-08 07:44:33 | Chimerix: 3Q Earnings Snapshot
2018-11-08 07:00:00 | Chimerix Announces Third Quarter 2018 Financial Results
2018-11-07 08:14:16 | Chimerix to Present at the Stifel 2018 Healthcare Conference
2018-11-05 14:29:22 | The most valuable public companies in the Triangle Slideshow
2018-11-01 08:00:00 | Chimerix to Announce Third Quarter 2018 Financial Results on November 8, 2018
2018-10-24 07:25:00 | Report: Developing Opportunities within Univar, Aqua America, Chimerix, Superior Energy Services, TechTarget, and ZIOPHARM Oncology — Future Expectations, Projections Moving into 2018
2018-10-11 16:01:00 | Chimerix to Host Annual Investor Update on October 17, 2018